46.26 USD
+0.18 (+0.39%)
46.26 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 83% to SUPN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 61.71. This target is 33.4% above the current price.
SUPN was analyzed by 12 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about SUPN.
In the previous month the buy percentage consensus was at a similar level.
SUPN was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-29 | B of A Securities | Initiate | Buy |
| 2025-10-23 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-09 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2025-09-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-08-06 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-02-26 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2025-02-19 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-09-11 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-02-28 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-09 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-10-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-05-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-01-23 | Piper Sandler | Maintains | Overweight |
| 2022-08-31 | Piper Sandler | Maintains | Overweight |
| 2021-04-13 | Jefferies | Upgrade | Hold -> Buy |
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
What do analysts expect the price target to be for SUPERNUS PHARMACEUTICALS INC (SUPN)?
12 analysts have analysed SUPN and the average price target is 61.71 USD. This implies a price increase of 33.4% is expected in the next year compared to the current price of 46.26.
How do analysts rate SUPERNUS PHARMACEUTICALS INC (SUPN)?
The consensus rating for SUPERNUS PHARMACEUTICALS INC (SUPN) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.